Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gradiant Corporation (035080.KQ)
Seoul, KR
Gradiant Corporation and its subsidiaries conduct e-commerce operations across South Korea, Vietnam, China, and various international regions. The company's activities are structured into several segments: Holding Business, Industrial B2B E-Commerce Business, Bio Healthcare Business, and Other Business. Gradiant primarily dedicates its efforts to three core areas: life sciences and healthcare, environmental and energy solutions, and creative learning platforms. Its diverse offerings include electric vehicle charging services, organoid research, venture capital financing for the biotech industry, advertising solutions, and logistics agency support, in addition to an online creative education platform. The company is also involved in sourcing and distributing pharmaceutical drugs and medical supplies to hospitals, developing oncology treatments, and designing, manufacturing, and commercializing adhesive films for electronic devices like smartphones. Furthermore, it supplies MRO (Maintenance, Repair, and Operations) and industrial consumables via online channels. Gradiant also participates in investment ventures, consulting, and freight transportation brokerage and agency services. Founded in 1995 and based in Seoul, South Korea, the company was known as Interpark Co., Ltd. until it rebranded to Gradiant Corporation in February 2022.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.69% | -5.44% | -18.90% | -17.90% | -16.79% | -13.75% | -33.67% | -51.78% | -58.41% | -72.40% | +5.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Software - Application: +13.0%-7.7% Q1'26: +12.6% (vs Q1'25)
-
EPS growth Software - Application: +28.6%-0.3% Q1'26: +85.3% (vs Q1'25)
-
FCF margin FCF growth · Software - Application: +45.3%-0.4% Q1'26: -2.1% (vs Q1'25)
-
EBIT margin Software - Application: +9.4%-0.6% Q1'26: +0.7% (vs Q1'25)
-
ROIC Software - Application: +7.5%-3.1% Q1'26: +2.1% (vs Q1'25)
-
Share dilution Software - Application: +0.0%+0.4% Q1'26: -10.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Software - Application: -1.16×6.95× ★ Q1'26: 3.13× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
|---|---|
| Revenue |
3.41T
est: 3.72B (+91,678.7%)
|
| EBITDA |
84.68B
est: 69.08M (+122,476.2%)
|
| EBIT |
28.95B
est: 13.39M (+216,098.3%)
|
| Net Income |
-4.76B
|
| SGA |
139.31B
est: 24.06M (+578,966.7%)
|
| EPS |
-444.10
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-18 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 1.7K | 0.42% |
| 2 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 120.3K | 0.33% |
| 3 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 231.68 | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| ChangHwak Lee | MD & Finance Officer | — | — |
| Hak-jae Kim | MD & Head of Management Support Officer | — | — |
| In-Bong Nam | Chief Executive Officer & Director | — | male |
| JinGeun Lee | MD & Head of Bio Group | — | — |
| Ki-Hyoung Lee | Chairman & Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 035080.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
